{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:30Z","timestamp":1792788450109,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Ulm","id":[{"id":"https:\/\/ror.org\/05emabm63","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Von Hippel-Lindau (VHL)-associated retinal hemangioblastomas (RHs) may cause vision-threatening exudation and hemorrhage. Conventional local therapies may be limited in advanced, recurrent, or anatomically high-risk lesions. This study evaluated ocular outcomes and observed tolerability during oral belzutifan treatment in a real-world cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between January 2023 and June 2025, this retrospective observational study included five consecutive patients with genetically confirmed VHL, contributing seven eyes; each eye had at least one RH that progressed despite prior conventional local therapy. Patients received oral belzutifan 120\u00a0mg once daily. Median on-treatment follow-up (FU) was 43 weeks (IQR, 27\u201350); median documented cumulative belzutifan exposure was 43 weeks (range, 27\u201350). Data were available through January 2026. Tumor regression was quantified as the relative change in projected pixel area from baseline to last on-treatment FU. The largest baseline lesion per fundus-imaged eye was predefined for the primary analysis; all fundus-imaged lesions were assessed exploratorily. Fourteen fundus-imaged RHs were included in the projected-pixel-area analyses, and one MRI-assessed RH was reported separately. Three retinal specialists independently performed lesion measurements and exploratory overall ocular response (OOR) grading as separate assessments. Readers were masked to one another\u2019s assessments; quantitative lesion measurements were additionally masked to patient information, treatment course, and image chronology. Safety was monitored within an interdisciplinary clinical framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the predefined primary descriptive analysis of the largest baseline lesion per fundus-imaged eye (six eyes from four patients), all six index lesions regressed (median projected-pixel-area reduction, 58.3%; IQR, 17.2\u201364.7%). All four lesions in the patient-level sensitivity analysis regressed (median, 59.6%; range, 14.5\u201364.8%). Across all 14 fundus-imaged lesions, median regression was 57.2% (IQR, 28.5\u201366.9%), and 11\/14 lesions (78.6%) showed\u2009&gt;\u200920% regression. All three readers classified all six evaluable eyes as improved. Exudative retinal detachment resolved in three of four affected eyes. Drug-related adverse events were mostly mild to moderate and manageable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Oral belzutifan was associated with RH regression and improved exudative disease activity in this selected real-world cohort. These findings support systemic HIF-2\u03b1 inhibition as a potential adjunctive therapeutic option for selected patients with progressive or anatomically high-risk ocular VHL disease. Prospective validation is required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>not applicable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00932-0","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:43:50Z","timestamp":1789371830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral belzutifan treatment in von hippel-lindau-associated retinal hemangioblastoma: a promising approach"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4134-091X","authenticated-orcid":false,"given":"Adnan","family":"Kilani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Jochem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Laible","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melih","family":"Parlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesam","family":"Alkabouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"issue":"12","key":"932_CR1","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1097\/IAE.0000000000002555","volume":"39","author":"ME Aronow","year":"2019","unstructured":"Aronow ME, Wiley HE, Gaudric A, Krivosic V, Gorin MB, Shields CL, et al. VON HIPPEL-LINDAU DISEASE: Update on Pathogenesis and Systemic Aspects. Retina. 2019;39(12):2243\u201353.","journal-title":"Retina"},{"issue":"1","key":"932_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrc3844","volume":"15","author":"L Gossage","year":"2015","unstructured":"Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"932_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000539434","volume":"10","author":"F Jamshidi","year":"2024","unstructured":"Jamshidi F, Lozano L, Tucker B, Andorf J, Sohn E, Stone E, et al. Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature. Ocul Oncol Pathol. 2024;10(3):154\u201361.","journal-title":"Ocul Oncol Pathol"},{"issue":"22","key":"932_CR4","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021;385(22):2036\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"932_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ophtha.2007.03.009","volume":"115","author":"WT Wong","year":"2008","unstructured":"Wong WT, Agron E, Coleman HR, Tran T, Reed GF, Csaky K, et al. Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel-Lindau disease. Ophthalmology. 2008;115(1):181\u20138.","journal-title":"Ophthalmology"},{"issue":"10","key":"932_CR6","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0161-6420(02)01177-6","volume":"109","author":"AD Singh","year":"2002","unstructured":"Singh AD, Nouri M, Shields CL, Shields JA, Perez N. Treatment of retinal capillary hemangioma. Ophthalmology. 2002;109(10):1799\u2013806.","journal-title":"Ophthalmology"},{"issue":"7","key":"932_CR7","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/S0161-6420(02)01059-X","volume":"109","author":"UM Schmidt-Erfurth","year":"2002","unstructured":"Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology. 2002;109(7):1256\u201366.","journal-title":"Ophthalmology"},{"issue":"1","key":"932_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jcma.2013.09.001","volume":"77","author":"FY Tsai","year":"2014","unstructured":"Tsai FY, Lau LI, Chen SJ, Lee FL, Lee SM. Persistent exudative retinal detachment after photodynamic therapy and intravitreal bevacizumab injection for multiple retinal capillary hemangiomas in a patient with von Hippel-Lindau disease. J Chin Med Assoc. 2014;77(1):52\u20136.","journal-title":"J Chin Med Assoc"},{"issue":"12","key":"932_CR9","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1097\/IAE.0000000000002572","volume":"39","author":"HE Wiley","year":"2019","unstructured":"Wiley HE, Krivosic V, Gaudric A, Gorin MB, Shields C, Shields J, et al. Management of Retinal Hemangioblastoma in Von Hippel-Lindau Disease. Retina. 2019;39(12):2254\u201363.","journal-title":"Retina"},{"issue":"3","key":"932_CR10","first-page":"71","volume":"3","author":"A Saitta","year":"2014","unstructured":"Saitta A, Nicolai M, Giovannini A, Mariotti C. Juxtapapillary retinal capillary hemangioma: new therapeutic strategies. Med Hypothesis Discov Innov Ophthalmol. 2014;3(3):71\u20135.","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"issue":"12","key":"932_CR11","first-page":"e76598","volume":"16","author":"NM Mohamad","year":"2024","unstructured":"Mohamad NM, Shokri SS, Sukaimy FS, Wan Muda WN, Ahmad Tajudin LS. Therapeutic Dilemma of a Juxtapapillary Retinal Capillary Hemangioma. Cureus. 2024;16(12):e76598.","journal-title":"Cureus"},{"issue":"8","key":"932_CR12","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00417-014-2660-0","volume":"252","author":"Y Wang","year":"2014","unstructured":"Wang Y, Abu-Asab MS, Shen D, Zhuang Z, Chew EY, Chan CC. Upregulation of hypoxia-inducible factors and autophagy in von Hippel-Lindau-associated retinal hemangioblastoma. Graefes Arch Clin Exp Ophthalmol. 2014;252(8):1319\u201327.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"932_CR13","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.ophtha.2024.05.024","volume":"131","author":"HE Wiley","year":"2024","unstructured":"Wiley HE, Srinivasan R, Maranchie JK, Chhablani J, Iversen ABB, Kruse A, et al. Oral Hypoxia-Inducible Factor 2alpha Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study. Ophthalmology. 2024;131(11):1324\u201332.","journal-title":"Ophthalmology"},{"key":"932_CR14","doi-asserted-by":"publisher","unstructured":"Dameron CM, Maja AK, Mehra D, Batra NN. Belzutifan as the primary treatment of bilateral juxtapapillary retinal hemangioblastoma in a patient with von hippel-lindau disease. J Vitreoretin Dis. 2024;9(3). https:\/\/doi.org\/10.1177\/24741264241309684","DOI":"10.1177\/24741264241309684"},{"issue":"10","key":"932_CR15","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S1470-2045(24)00389-9","volume":"25","author":"O Iliopoulos","year":"2024","unstructured":"Iliopoulos O, Iversen AB, Narayan V, Maughan BL, Beckermann KE, Oudard S, et al. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2024;25(10):1325\u201336.","journal-title":"Lancet Oncol"},{"key":"932_CR16","doi-asserted-by":"publisher","first-page":"102011","DOI":"10.1016\/j.ajoc.2024.102011","volume":"33","author":"CW Ercanbrack","year":"2024","unstructured":"Ercanbrack CW, Elhusseiny AM, Sanders RN, Santos Horta E, Uwaydat SH. Belzutifan-induced regression of retinal capillary hemangioblastoma: A case-series. Am J Ophthalmol Case Rep. 2024;33:102011.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"932_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/ICB.0000000000001516","volume":"19","author":"CC Cotton","year":"2025","unstructured":"Cotton CC, Chandrabhatla AS, Andrews PH, Purrow BW, Shildkrot YE. Belzutifan for Treatment of Giant Retinal Hemangioblastoma with Extrascleral Extension Associated with Von Hippel-Lindau Syndrome. Retin Cases Brief Rep. 2025;19(1):66\u20139.","journal-title":"Retin Cases Brief Rep"},{"key":"932_CR18","unstructured":"Services USDoHaH. Common terminology criteria for adverse events (CTCAE) Version 5.0. Bethesda, MD: National Institutes of Health; National Cancer Institute. 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"issue":"8","key":"932_CR19","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.4103\/IJO.IJO_1684_23","volume":"72","author":"M Ketkar","year":"2024","unstructured":"Ketkar M, Raval VR, Reddy PVA, Kannan K, Kaliki S. Indocyanine green-enhanced transpupillary thermotherapy for juxtapapillary retinal capillary hemangioblastoma. Indian J Ophthalmol. 2024;72(8):1150\u20135.","journal-title":"Indian J Ophthalmol"},{"issue":"5","key":"932_CR20","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s11096-025-01953-9","volume":"47","author":"Y Ye","year":"2025","unstructured":"Ye Y, Fan B, Hu X. A real-world pharmacovigilance study of belzutifan in renal cell carcinoma and von Hippel-Lindau disease: insights from the FDA adverse event reporting system database. Int J Clin Pharm. 2025;47(5):1447\u201357.","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"932_CR21","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ophtha.2023.12.014","volume":"131","author":"AB Daniels","year":"2024","unstructured":"Daniels AB, Chang EY, Chew EY, Gombos DS, Gorin MB, Shields CL, et al. Consensus Guidelines for Ocular Surveillance of von Hippel-Lindau Disease. Ophthalmology. 2024;131(5):622\u201333.","journal-title":"Ophthalmology"},{"issue":"4","key":"932_CR22","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/IAE.0000000000001601","volume":"38","author":"X Chen","year":"2018","unstructured":"Chen X, Sanfilippo CJ, Nagiel A, Hosseini H, Mitchell D, McCannel CA, et al. Early Detection of Retinal Hemangioblastomas in Von Hippel-Lindau Disease Using Ultra-Widefield Fluorescein Angiography. Retina. 2018;38(4):748\u201354.","journal-title":"Retina"},{"key":"932_CR23","first-page":"3979304","volume":"2026","author":"M Belmouhand","year":"2026","unstructured":"Belmouhand M, Kiilgaard JF, Faber C. Montage Error in Ultra-Widefield Imaging of Retinal Hemangioblastomas. Case Rep Ophthalmol Med. 2026;2026:3979304.","journal-title":"Case Rep Ophthalmol Med"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00932-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00932-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00932-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:52:51Z","timestamp":1789494771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00932-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00932-0","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Following review of the anonymized dataset and the patients\u2019 signed informed consent forms, the Ethics Committee of Ulm University waived the requirement for additional formal ethics approval due to the retrospective design and complete anonymization of the data. All patients had provided written informed consent for the use of clinical data and imaging for research purposes. No reference number was assigned.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of anonymized clinical data and ophthalmic images was obtained from all patients.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used DeepL (DeepL SE, Cologne, Germany) and ChatGPT (OpenAI, San Francisco, CA, USA) to improve the clarity, readability, and language quality of the text. These tools were used only for language editing and editorial refinement and not for data analysis, image interpretation, or generation of scientific conclusions. All content generated or modified with their assistance was carefully reviewed, verified, and edited by the authors. The authors take full responsibility for the integrity and accuracy of the final manuscript.","order":4,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"125"}}